Organization (Industry)
TANDEM DIABETES CARE, INC.
ClinicalTrials.gov lists TANDEM DIABETES CARE, INC. as lead sponsor of 21 trials, counting the companies grouped under it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 4 registered with a 2026 start date. The dashed outline is the pace from the 4 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.2 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers TANDEM DIABETES CARE, INC. and 1 company grouped under it: 21 lead-sponsored trials (18 its own, 3 in the grouped companies) and 3 legal-entity registrations (3 its own, 0 in the grouped companies).
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| Capillary Biomedical, Inc. | 3 | 0 |
Disease areas (8)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 46 |
| Diabetes Mellitus, Type 1 | 42 |
| Hypoglycemia | 4 |
| Diabetes Mellitus, Type 2 | 3 |
| Insulin Resistance | 1 |
Showing 5 of 8 disease areas.
Trials by start year as sponsor or collaborator (13)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 5 |
| 2024 | 4 |
| 2023 | 3 |
| 2022 | 4 |
| 2021 | 7 |
| 2020 | 7 |
| 2019 | 4 |
| 2018 | 2 |
| 2017 | 3 |
Showing 10 of 13 years.
Recruitment duration, a model prediction: none of the 18 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 82% hit target (n=11) | 36% on time (n=11) |
Journals published in (15)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Diabetes technology & therapeutics | 23 |
| Diabetes care | 9 |
| The New England journal of medicine | 4 |
| Journal of diabetes science and technology | 3 |
| Pediatric diabetes | 3 |
Showing 5 of 15 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 193 | 81 | 2025-12-30 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 1,014,736,000 | -204,710,000 | 193,114,000 |
| 2024 | 940,203,000 | -96,025,000 | 198,877,000 |
| 2023 | 747,718,000 | -222,611,000 | 169,667,000 |
| 2022 | 801,217,000 | -94,594,000 | 139,114,000 |
| 2021 | 702,799,000 | 15,566,000 | 92,054,000 |
| 2020 | 498,830,000 | -34,382,000 | 63,574,000 |
| 2019 | 362,305,000 | -24,753,000 | 45,199,000 |
| 2018 | 183,866,000 | -122,611,000 | 29,227,000 |
| 2017 | 107,601,000 | -73,033,000 | 20,661,000 |
| 2016 | 84,248,000 | -83,447,000 | 18,809,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (9)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-02-27 | Private placement | 290,700,000 | Sec extracted |
| 2026-02-25 | Other financing | not disclosed | Sec extracted |
| 2025-05-21 | Other financing | not disclosed | Sec extracted |
| 2024-03-08 | Private placement | 306 | Sec extracted |
| 2024-03-08 | Private placement | not disclosed | Sec extracted |
Showing 5 of 9 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 6 |
FDA recalls (13)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| Tandem pumps are battery-operated infusion pumps capable of both basal and bolus delivery of insulin. The pumps utilize a motor-driven mechanism to deliver insulin from within a disposable cartridge, through an infusion set, into a patient s subcutaneous tissue. As with current insulin infusion pumps on the U.S. market, the desired timing and quantity of the insulin delivery is programmed by the user (i.e., the patient). | Class II | 2026-01-30 |
| Tandem Mobi Insulin Pump: Description/Catalog: Tandem insulin pumps are battery-operated infusion pumps capable of both basal and bolus delivery of insulin. The pumps utilize a motor-driven mechanism to deliver insulin from within a disposable cartridge, through an infusion set, into a patient s subcutaneous tissue. As with current insulin infusion pumps on the U.S. market, the desired timing and quantity of the insulin delivery is programmed by the user (i.e., the patient). Pump, Tandem Mobi, Control-IQ/1010750, Pump, Tandem Mobi, Control-IQ, Replacement/1012719, Pump, Tandem Mobi, Control-IQ 7.6.0.3, Medicare/1013501, Pump, Tandem Mobi, Control-IQ 7.7/1013655, Pump, Tandem Mobi, Control-IQ, 7.7, Replacement/1013656, Pump, Tandem Mobi, Control-IQ 7.7, Medicare/1013700, Pharmacy Kit, Starter Pack, Tandem Mobi 7.7/1014081 | Class I | 2025-10-06 |
| t:slim X2 insulin pump with Interoperable Technology, Control-IQ+ technology, REF: 1014070, 1014071, 1014072, 1014073, and User Guide when using Dexcom G7 sensor; Tandem Mobi insulin pump with Interoperable Technology, Control-IQ+ technology, REF: 1014801, 1014811, 1014813, and User Guide when using Dexcom G7 sensor | Class II | 2025-08-05 |
| Battery Operated infusion pumps. t:slim X2 G5, Replacement, Refurbished, REF: 1000911; t:slim X2 GS Classic, Replacement, Refurbished, REF: 1003808; t: slim X2, Basal-IQ, mg/dl, REF: 1004219; Pump, t:slim X2, Clinical Use Only, REF: 1004484; Pump, t:slim X2, Control-IQ, REF: 1005611; Pump, t:slim X2, Control-IQ, mmoUL, Refurbished Replacement, REF: 1005613; Pump, t:slim X2, Control-IQ, mg/dl, REF: 1005615; Pump, t:slim X2, Control-IQ, mg/dl, Refurbished Replacement, REF: 1005617; Pump, t:slim X2, Basal-IQ 6.4, Refurbished Replacement, REF: 1006379; Pump, t:slim X2, Control-IQ 7.4, REF: 1006402; Pump, t:slim X2, Control-IQ 7.4, Replacement, REF: 1006406; Pump, t:slim X2, Control-IQ 7.4, REF: 1006408; Pump, t:slim X2, Basal-IQ, , REF: 1006419; Pump, t:slim X2, Basal-IQ, mg/dL, REF: 1006420; Pump, t:slim X2, Basal-IQ, mmoUL, Refurbished Replacement, REF: 1006535; Pump, t:slim X2, Basal-IQ, mg/dL, Refurbished Replacement, REF: 1006537; Pump, t:slim X2, Control-IQ, mg/dl , Replacement, REF: 1008255; Pump, t:slim X2, Control-IQ, mmoUL, Replacement, REF: 1008256; Pump, t:slim X2, Basal-IQ, mmoUL, Replacement, REF: 1008257; Pump, t:slim X2, Basal-IQ, mg/dl ,Replacement, REF: 1008258; Pump, t:slim X2, Basal-IQ, REF: 1010004; Pump, t:slim X2, Basal-IQ, Replacement, REF: 1010005; Pump, t:slim X2, Basal-IQ, Medicare, REF: 1010006; Pump, t:slim X2, Basal-IQ, Medicare, REF: 1010007; Pump, t:slim X2, Control-IQ, REF: 1010009; Pump, t:slim X2, Control-IQ Replacement, REF: 1010010; Pump, t:slim X2, Control-IQ, Medicare, REF: 1010011; Pump, t:slim X2, Control-IQ, Refurbished Replacement, REF: 1010012; Pump, t:slim X2, Control-IQ, REF: 1012867; Pump, t:slim X2, Control-IQ, Medicare, REF: 1012868; Pump, t:slim X2, Control-IQ, Replacement, REF: 1012869; Pump, t:slim X2, Control-IQ 7.8, REF: 1013195; Pump, t:slim X2, Control-IQ 7.8, Medicare, REF: 1013196; Pump, t :slim X2, Control-IQ 7.8, Replacement, REF: 1013197; Pump, t:slim X2, Control-IQ 7.8, Refurbished Replacement, REF: 1013198 | Class I | 2025-07-21 |
| t:slim X2 Insulin Pump with Interoperable Technology (with Tandem t:slim mobile app) | Class II | 2025-07-03 |
Showing 5 of 13 recalls.
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 1 | 2024-05-21 |
Manufacturing and distribution sites (5)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Tandem Diabetes Care, INC. | San Diego, US | FDA | |
| TANDEM DIABETES CARE, INC. | San Diego, US | FDA | |
| TANDEM DIABETES CARE, INC. | San Diego, US | FDA | |
| TANDEM DIABETES CARE, INC. | Irvine, US | FDA | |
| TANDEM DIABETES CARE, INC. | San Diego, US | FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (27)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| University of Virginia | Co sponsors trial with | 14 |
| Government of the United States of America | Co sponsors trial with | 13 |
| Jaeb Center for Health Research | Co sponsors trial with | 11 |
| Sue Brown | Co sponsors trial with | 4 |
| Marc Breton | Co sponsors trial with | 3 |
Showing 5 of 27 relationships.
Latest dated events (271)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-05-14 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-03-03 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-02-27 | Private placement | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-02-25 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 271 events.
Biomarker capability evidence (186)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AICDA | Trial sponsor | Named in trial inclusion criteria |
| AICDA | Trial collaborator | Named in trial inclusion criteria |
| AICDA | Trial collaborator | Named in trial inclusion criteria |
| AICDA | Trial sponsor | Named in trial inclusion criteria |
| AICDA | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 186 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, active development programs, approved assets, fda warning letters, fda untitled letters, clia clinical laboratory certificates, and biomarkers this organization publishes on.